



HAL
open science

High-throughput Sequencing of a 4.1 Mb Linkage Interval Reveals FLVCR2 Deletions and Mutations in Lethal Cerebral Vasculopathy

Sophie Thomas, Ferechte Encha-Razavi, Louise Devisme, Heather C Etchevers, Bettina Bessieres-Grattagliano, Geraldine Goudefroye, Nadia Elkhartoufi, Emilie Pateau, Amale Ichkou, Maryse Bonniere, et al.

► To cite this version:

Sophie Thomas, Ferechte Encha-Razavi, Louise Devisme, Heather C Etchevers, Bettina Bessieres-Grattagliano, et al.. High-throughput Sequencing of a 4.1 Mb Linkage Interval Reveals FLVCR2 Deletions and Mutations in Lethal Cerebral Vasculopathy. *Human Mutation*, 2010, 31 (10), pp.1134. 10.1002/humu.21329 . hal-00574003

HAL Id: hal-00574003

<https://hal.science/hal-00574003>

Submitted on 7 Mar 2011

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.



High-throughput Sequencing of a 4.1 Mb Linkage Interval Reveals *FLVCR2* Deletions and Mutations in Lethal Cerebral Vasculopathy

Journal:	<i>Human Mutation</i>
Manuscript ID:	humu-2010-0234.R1
Wiley - Manuscript type:	Research Article
Date Submitted by the Author:	18-Jun-2010
Complete List of Authors:	<p>THOMAS, Sophie; INSERM U781, Genetics; Université René Descartes</p> <p>ENCHA-RAZAVI, Ferechte; INSERM U781, Genetics; Université René Descartes</p> <p>DEVISME, Louise; CHRU de Lille, Pôle de Pathologie, Centre de Biologie Pathologie</p> <p>Etchevers, Heather; INSERM U-781, Genetics; Université René Descartes</p> <p>Bessieres-Grattagliano, Bettina; ADHMI Institut de Puériculture et de Périnatalogie, Anatomo-foeto-pathologie</p> <p>GOUDEFROYE, Geraldine; Hôpital Necker-Enfants Malades, APHP, Genetics</p> <p>ELKHARTOUFI, Nadia; Hôpital Necker-Enfants Malades, APHP, Genetics</p> <p>Pateau, Emilie; CEA, DSV, Institut de Génomique, Genoscope, Centre National de Séquençage</p> <p>ICKKOU, Amale; Hôpital Necker-Enfants Malades, APHP, Genetics</p> <p>Bonniere, Maryse; APHP Necker, Embryologie; Laboratoire Nord Pathologie</p> <p>Marcorelles, Pascale; CHRU Hôpital Morvan, Anatomopathologie Pathologique</p> <p>PARENT, Philippe; CHRU Hôpital Morvan, Département de pédiatrie et génétique médicale</p> <p>Manouvrier, Sylvie; CHRU de Lille, Hôpital Jeanne de Flandre, Service de Génétique Clinique et Université Lille 2</p> <p>HOLDER, Muriel; CHRU de Lille, Hôpital Jeanne de Flandre, Service de Génétique Clinique et Université Lille 2</p> <p>Laquerriere, Annie; CHU Rouen, Anatomie pathologique</p> <p>Loeuillet, Laurence; CHI Poissy, Service d'Anatomie et de Cytologie Pathologiques</p> <p>ROUME, Joelle; CHI Poissy, Génétique Médicale</p> <p>MARTINOVIC, Jéléna; Assistance Publique - Hôpitaux de Paris, APHP, Genetics; Hôpital Necker-Enfants Malades, APHP, Genetics</p>

	<p>MOUGOU-ZERELLI, Soumaya; Université René Descartes; INSERM U781, Genetics; Hôpital Farhat Hached, Génétique moléculaire et Biologie de la reproduction</p> <p>Gonzales, Marie; APHP, Armand Trousseau, Université Pierre et Marie Curie, Paris 6, Génétique et Embryologie Médicales</p> <p>MEYER, Vencent; CEA, DSV, Institut de Génomique, Genoscope, Centre National de Séquençage</p> <p>Wessner, Marc; CEA, DSV, Institut de Génomique, Genoscope, Centre National de Séquençage</p> <p>Bole Feysot, Christine; Fondation IMAGINE, Plateforme de génomique,</p> <p>Nitschke, Patrick; Université Paris - Descartes, Service de Bioinformatique</p> <p>Leticée, Nadia; Hopital Necker-Enfants Malades, APHP, Service de Gynécologie Obstétrique</p> <p>Munnich, Arnold; Hôpital Necker-Enfants Malades, APHP, Genetics; Université René Descartes; INSERM U781, Genetics</p> <p>LYONNET, Stanislas; Hôpital Necker-Enfants Malades, APHP, Genetics; Université René Descartes; INSERM U781, Genetics</p> <p>Wookey, Peter; University of Melbourne, Department of Medicine</p> <p>Gyapay, Gabor; CEA, DSV, Institut de Génomique, Genoscope, Centre National de Séquençage</p> <p>Folliguet, Bernard; Maternite de Nancy, Laboratoire de Biologie de la Reproduction et du Développement</p> <p>VEKEMANS, Michel; Hôpital Necker-Enfants Malades, APHP, Genetics; Université René Descartes; INSERM U781, Genetics</p> <p>ATTIE-BITACH, Tania; INSERM U-781, Genetics; Hôpital Necker-Enfants Malades, Département de Génétique; Université René Descartes</p>
Key Words:	Fowler syndrome, cerebral proliferative vasculopathy, <i>FLVCR2</i> , Hydranencephaly, Fetal lethality, Arthrogryposis



1
2
3 **High-throughput** Sequencing of a 4.1 Mb Linkage Interval Reveals *FLVCR2* Deletions
4 and Mutations in Lethal Cerebral Vasculopathy
5
6
7

8 Sophie Thomas^{1,2}, Ferechté Encha-Razavi^{1,2,3}, Louise Devisme⁴, Heather Etchevers^{1,2},
9 Bettina Bessieres-Grattagliano⁵, Géraldine Goudefroye³, Nadia Elkhartoufi³, Emilie
10 Pateau⁶, Amale Ichkou³, Maryse Bonnière^{3,7}, Pascale Marcorelle⁸, Philippe Parent⁹,
11 Sylvie Manouvrier¹⁰, Muriel Holder¹⁰, Annie Laquerrière¹¹, Laurence Loeuillet¹², Joelle
12 Roume¹³, Jelena Martinovic³, Soumaya Mougou-Zerelli^{1,2,14}, Marie Gonzales¹⁵, Vincent
13 Meyer⁶, Marc Wessner⁶, Christine Bole Feysot¹⁶, Patrick Nitschke¹⁷, Nadia Leticee¹⁸,
14 Arnold Munnich^{1,2,4}, Stanislas Lyonnet^{1,2,4}, Peter Wookey¹⁹, Gabor Gyapay⁶, Bernard
15 Foliguet²⁰, Michel Vekemans^{1,2,4}, Tania Attié-Bitach^{1,2,4}
16
17
18
19
20
21
22

23 1- INSERM U-781, Hôpital Necker-Enfants Malades, Paris, France

24 2- Université René Descartes, Paris 5, France

25 3- Département de Génétique, Hôpital Necker-Enfants Malades, AP-HP, Paris, France

26 4- Pôle de Pathologie, Centre de Biologie Pathologie, CHRU Lille, France

27 5- Laboratoire d'Anatomo-Foeto-Pathologie, Institut de Puériculture et de Périnatalogie,
28 Paris, France

29 6- CEA, DSV, Institut de Génomique, Genoscope, Evry, France

30 7- Laboratoire Nord Pathologie, Lille, France

31 8 - Laboratoire d'anatomopathologie, CHRU Hôpital Morvan, Brest, France

32 9 - Département de pédiatrie et génétique médicale, CHRU Hôpital Morvan, Brest,
33 France

34 10- Service de Génétique Clinique et Université Lille 2, CHRU de Lille, Hôpital Jeanne
35 de Flandre, Lille, France

36 11- Laboratoire d'Anatomie Pathologique, Hôpital de Rouen, Rouen, France

37 12- Service d'Anatomie et de Cytologie Pathologiques, CHI Poissy, Saint Germain en
38 Laye, France

39 13 - Génétique Médicale, CHI Poissy, Saint Germain en Laye, France

40 14 - Service de Cytogénétique, Génétique moléculaire et Biologie de la reproduction,
41 Hôpital Farhat Hached, Sousse, Tunisie
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 15- Service de Génétique et d'Embryologie Médicales, Hôpital Armand Trousseau, AP-
4 HP, et Université Pierre et Marie Curie, Paris 6, France
5

6
7 16- Plateforme de génomique, Fondation IMAGINE
8

9 17- Service de Bioinformatique, Université Paris - Descartes
10

11 18- Service de Gynécologie Obstétrique, Hôpital Necker Enfants Malades, Paris, France
12

13 19- Department of Medicine, University of Melbourne, Australia
14

15 20- Laboratoire de Biologie de la Reproduction et du Développement, Maternité de
16 Nancy, France
17

18
19
20 Corresponding author:
21

22
23 Tania ATTIE-BITACH
24

25
26 Département de Génétique et Unité INSERM U-781
27

28
29 Hôpital Necker-Enfants Malades, Paris, France
30

31
32 Tel: 33 (0) 1 44 49 51 44
33

34
35 Fax: 33 (0) 1 44 49 51 50
36

37
38 Email: tania.attie@inserm.fr
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

ABSTRACT:

Rare lethal disease gene identification remains a challenging issue, but it is amenable to new techniques in high-throughput sequencing (HTS). Cerebral proliferative glomeruloid vasculopathy (PGV), or Fowler syndrome, is a severe autosomal recessive disorder of brain angiogenesis, resulting in abnormally thickened and aberrant perforating vessels leading to hydranencephaly. In 3 multiplex consanguineous families, genome-wide SNP analysis identified a locus of 14 Mb on chromosome 14. In addition, 280 consecutive SNPs were identical in two Turkish families unknown to be related, suggesting a founder mutation reducing the interval to 4,1Mb. To identify the causative gene, we then specifically enriched for this region with sequence capture and performed HTS in a proband of 7 families. Due to technical constraints related to the disease, the average coverage was only 7X. Nonetheless, iterative bioinformatic analyses of the sequence data identified mutations and a large deletion in the *FLVCR2* gene, encoding a twelve transmembrane domain-containing putative transporter. A striking absence of alpha-smooth muscle actin immunostaining in abnormal vessels in fetal PGV brains, suggests a deficit in pericytes, cells essential for capillary stabilisation and remodelling during brain angiogenesis. This is the first lethal disease-causing gene to be identified by comprehensive HTS of an entire linkage interval.

Key words Fowler syndrome, cerebral proliferative vasculopathy, *FLVCR2*, hydranencephaly, fetal lethality, arthrogryposis

INTRODUCTION

Cerebral proliferative glomeruloid vasculopathy (PGV) is a severe autosomal recessive disorder of brain angiogenesis, resulting in abnormally thickened and aberrant perforating vessels, forming glomeruloids with inclusion-bearing endothelial cells. This peculiar vascular malformation was delineated by Fowler in 1972 in relation to a stereotyped, lethal fetal phenotype (OMIM 225790), associating hydranencephaly and hydrocephaly with limb deformities (Fowler, et al., 1972). PGV disrupts the developing central nervous system (CNS) but the reason for which abnormal angiogenesis is restricted to the CNS parenchyme remains unknown. Arthryogryposis, when present, appears to be a secondary result of CNS motoneuron degeneration, itself one potential outcome of perfusion failure. Since its earliest description, 42 PGV cases from 26 families have been reported on the basis of histological criteria (Bessieres-Grattagliano, et al., 2009; Williams, et al. 2010).

Identification of a causative gene for a very rare lethal syndrome is a challenge at many levels. The first issue is to find a family that allows the identification of a linkage interval. Such an interval may contain too many genes to make the classical subsequent strategy practical, consisting in designing primers that will permit sequencing of each exon of all the genes of the region. The second difficulty is that sequencing of all the exons is sometimes vain in light of the growing number of non-coding regions identified as pathogenic alleles (Benko, et al., 2009; Kleinjan and van Heyningen, 2005; Lettice, et al., 2003). Finally, for prenatally lethal syndromes such as PGV, technical constraints such as poor quality genomic DNA samples are added. Recent advances in biotechnology permit the sequencing of all the DNA, including the non-coding regions, in most genomic

1
2
3 intervals. After homozygosity mapping of a 4.1 Mb region, we applied targeted genome
4 capture by using a NimbleGen array and high-throughput Roche 454 GS FLX sequencing
5 to the genomic DNA of the proband of 6 families. Bioinformatic analysis of the data
6 allowed us to identify *FLVCR2* (MIM 610865) as the gene responsible for Fowler
7 syndrome (FS). High-throughput sequencing (HTS) generated false positive and false
8 negative results, in part due to insufficient sequencing coverage, and unless care is taken,
9 these can engender the risk of missing mutations during the analysis.
10
11
12
13
14
15
16
17
18
19
20
21
22
23

24 MATERIALS AND METHODS

25
26
27
28 **Patients :** The 7 families analysed have been previously reported (Families I to VII
29 (Bessieres-Grattagliano, et al., 2009)). Genomic DNA was extracted from frozen tissue or
30 cultured amniocyte cells in fetal cases and from peripheral blood samples for parents and
31 unaffected siblings.
32
33
34
35
36
37
38

39 **Genome linkage screening and linkage analysis:** Genome-wide homozygosity mapping
40 was performed using 250K Affymetrix SNP arrays in 5 affected and 3 unaffected
41 individuals of two Turkish and one French multiplex, consanguineous families. Data
42 were evaluated by calculating multipoint lod scores across the whole genome using
43 MERLIN software, assuming recessive inheritance with complete penetrance.
44
45
46
47
48
49
50

51 **NimbleGen Sequence capture and high-throughput sequencing:** A custom sequence
52 capture array was designed and manufactured by Roche NimbleGen (Madison, WI,
53 USA). 21 micrograms of genomic DNA was used for sequence-capture in accordance
54
55
56
57
58
59
60

1
2
3 with the manufacturer's instructions (Roche NimbleGen) and a final amount of 3
4
5 micrograms of amplified enriched DNA was used as input for generating a ssDNA
6
7 library for HTS; 25% lane of a Roche 454 GS FLX sequencer with Titanium reagents)
8
9 yielding 135 Mb of sequence data per sample.
10
11

12
13
14 **Capillary sequencing of *FLVCR2*** : Primers were designed in introns flanking the 10
15
16 exons using the "Primer 3" program (<http://fokker.wi.mit.edu/primer3/input.htm>) and are
17
18 listed in Supp. Table S2. PCR were all performed in the same conditions, with a
19
20 touchdown protocol consisting of denaturation for 30s at 96°C, annealing for 30s at a
21
22 temperature ranging from 64°C to 50°C (decreasing 1° during 14 cycles, then 20 cycles at
23
24 50°) and extension at 72°C for 30s. PCR products were treated with Exo-SAP IT (AP
25
26 Biotech), and both strands were sequenced with the appropriate primer and the "BigDye"
27
28 terminator cycle sequencing kit (Applied Biosystems Inc.) and analyzed on ABI3130
29
30 automated sequencers. Mutation numbering is based on cDNA reference sequence
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
NM_017791.

39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
Immunohistochemistry : Immunohistochemistry was carried out on six micrometer
selected sections using antisera directed against smooth muscle actin (diluted 1:800).
Immunohistochemical procedures included a classical microwave pre-treatment protocol
in citrate buffer to aid antigen retrieval. Incubations were performed for one hour at room
temperature, using the TECHMATE system (DAKOPATTS-Trappes-France). After
incubation, histological slides were processed using the LSAB detection kit
(DAKOPATTS-Trappes-France). Peroxidase was visualized by means of either 3-3'
diaminobenzidine or amino-ethyl carbazole.

RESULTS

We have collected DNA from fetuses of 7 families reported earlier (Families I to VII (Bessieres-Grattagliano, et al., 2009)). All 14 fetal cases bore the brain-specific angiogenic anomalies characteristic of PGV, resulting in thickened and aberrant perforating vessels and glomeruloids, as exemplified in Figure 1A. Endothelial cells (ECs) were positive for CD34 in both control fetal brains (Figure 1B) and in the tortuous glomerular capillaries (Figure 1C). VEGF-A, while not normally expressed by small brain capillaries (Figure 1D), was strikingly found in the glomerular ECs of PGV fetuses (Figure 1E arrowhead). Like normal Ecs though, PGV ECs expressed VEGFR2 and, weakly, Glut-1 (not shown). CD68, characteristic of macrophages, was completely absent (data not shown). Numerous GFAP-positive astrocytes were observed throughout the cerebral mantle, with immunoreactive endfeet juxtaposed to glomeruloids (Figure 1F). An antibody to alpha-smooth muscle actin (aSMA) stained vessels within the outer leptomeninges and the walls of perforating vessels in normal fetal brains (Figure 1G). In contrast, although PGV meningeal vessels had similar aSMA expression, the dysplastic intraparenchymous vessels were irregularly stained, if at all (Figure 1H), while most glomeruloid vessels were negative for aSMA (Figure 1I).

To find the molecular basis for this phenotype, we first undertook a genome-wide SNP analysis using an Affymetrix 250K SNP chip with 5 affected and 3 unaffected members of two Turkish and one French multiplex, consanguineous families. Informed consent was obtained from all patients and their relatives; clinical data of all families have previously been reported (Bessieres-Grattagliano, et al., 2009). Genome-wide linkage

1
2
3 analysis conducted with the MERLIN program revealed a 13 Mb genomic region on
4 chromosome 14 from rs10151019 to rs12897284, with a lodscore of 5.4. Moreover, four
5 affected sibs from the two Turkish families shared the same alleles for 280 consecutive
6 SNPs, suggesting a founder effect and reducing the interval to 4.1 MB, from rs2803958
7 to rs11159220. These two families originated from villages 12 km apart in
8 Khramanmaraps (central Turkey). Microsatellite marker analysis further confirmed the
9 same disease allele in both families, and showed linkage in 3 additional families (Figure
10 2).

11
12
13 To identify the causative gene, we applied array-based sequence capture of the complete
14 4.1 MB region followed by high-throughput sequencing. DNA from one proband of 6
15 families, the heterozygous mother from family I, and a healthy brother not carrying the
16 at-risk allele were selected (Figure 2). Coverage varied from 2X to 12X in individuals
17 depending on the integrity of their DNA (Table 1), with an average coverage depth of
18 7X; 60% (851,147) of the enriched reads were located on the targeted regions. Only 25%
19 of the targeted regions reached 10X coverage depth.

20
21
22 The number of the detected variations was too large to handle them manually. To
23 facilitate the analysis of these variations a specific genome browser was set up to
24 visualise the locations of variations on the genome, and at the same time an analysis tool
25 has been developed. This analysis tool applied a series of filters to the identified
26 variations. These filters were based on the following criteria: 1) the quality of the
27 sequence variant measured as the number of reads that detected the variant 2) the
28 presence or absence of variants in public databases such as dbSNP and HapMap. 3) the
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 presence or absence of the variants among the studied samples 4) annotation of the
4 sequence variants based on their location (intron, exon, etc ...) and the characteristics of
5 the resulting change such as synonymous, non-synonymous or stop mutation. Filtered
6 results were visualised in an interactive table permitting us to sort and analyse the results.
7
8 Thus, initial analysis of the sequence data that met an arbitrary threshold of at least three
9 reads, of which at least one was required to be in the opposing orientation, detected a
10 total of 23,262 variations, 17,031 of which were on chromosome 14 (73%, Table S1). Of
11 these, 3,457 variants were found to not correspond to known SNPs, and were absent from
12 the normal control individual (E). After initial exclusion of non-exonic and synonymous
13 variants, 42 variants in 29 candidate genes remained. In 20 of these genes, a single
14 variation was found in one individual, while two and three variations were found in six
15 and two genes, respectively (Figure 3).
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34

35 *FLVCR2* was the only gene with variations identified in four out of seven individuals. In
36 addition, careful examination of the *FLVCR2* locus in the proband of family II revealed a
37 homozygous deletion of exons 2 to 10, as the absence of both nucleotide variations and
38 reads over a 46.8 KB genomic region (Figure 4A). The deletion was confirmed to
39 segregate in families I and II, and cloning of the breakpoints revealed the inclusion of the
40 last two exons of the neighbouring *C14orf1* gene, with no repeated DNA sequences at the
41 boundaries. It is noteworthy that this deletion was not detected by Affymetrix 250K SNP
42 chip. Indeed, only one SNP was located in the non-deleted portion of intron 1. Direct
43 sequencing of the 10 exons of *FLVCR2* (Supp. Table S1), identified mutations in two
44 additional families (Table 1), such that mutant *FLVCR2* alleles were identified in each of
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 the 7 families studied (5 homozygotes and 2 compound heterozygotes; Table 1 and
4
5 Figure 4B).
6
7

8
9 Reasons for false-negative results using HTS approaches are summarized in Table 1, and
10 emphasize the need for complementary confirmation. In particular, in family IV, a second
11 heterozygous mutation was found by direct resequencing, although it had an apparently
12 homozygous mutation as indicated by the HTS analysis. In family III, the homozygous
13 mutation found with Sanger sequencing had only been read 2 times in the HTS and had
14 thus been excluded by the stringency of the filter. As a third example, the second
15 heterozygous mutation in family VII had been read 4 times but was excluded for
16 unidirectionality. Interestingly, in family VI, not known to be consanguineous, the
17 identical nonsense mutation was found in the 3 affected sibs (homozygous in fetuses and
18 heterozygous in parents), suggesting more distant consanguinity or a founder effect.
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33

34 FLVCR2 is a member of the major facilitator superfamily (MFS) of transporter proteins,
35 that shuttle small molecules in response to ion gradients (Pao, et al., 1991). Like other
36 MFS members, FLVCR2 is predicted to contain 12 membrane-spanning segments and six
37 extracellular loops. As shown in figure 5A, the 3 homozygous mutations are predicted to
38 alter an amino-acid localized to one transmembrane domain (TM) : TM2 in family VI,
39 TM8 in family III and TM10 in family V. In family IV, one of the 2 mutations alters an
40 amino-acid predicted to be localized in TM8 and the other in the intracellular loop 5.
41
42
43
44
45
46
47
48
49
50

51 Amino acid sequence alignment for FLVCR2 from 10 different species showed that T430
52 and G412 have been conserved since our common ancestor with *C. elegans*, whereas R84
53 has been conserved in common with *D. melanogaster* (Figure 5B). T352R and L398V
54
55
56
57
58
59
60

1
2
3 alter residues less evolutionary conserved, especially L398V. However, those mutations
4
5 are absent from both the dbSNP and the 1000 Genome database not yet integrated in
6
7 dbSNP. While the L398V mutation was predicted to be benign by the Polyphen algorithm
8
9 (<http://genetics.bwh.harvard.edu/pph/>), the T352R mutation as well as the other missense
10
11 mutations identified in this study were predicted to be damaging to protein function.
12
13 Thus, the pathogenicity of these two last mutations is likely but not totally proven. In
14
15 total, eight different mutations including one nonsense mutation (homozygous in family
16
17 VI), six missense mutations, and one homozygous deletion in two families (I and II) have
18
19 been found in *FLVCR2*.
20
21
22
23
24
25
26
27
28

29 DISCUSSION

30
31
32 PGV is a very rare and lethal genetic condition. Since its first description, 42 cases from
33
34 26 families have been reported on the basis of histological criteria of PGV (Bessieres-
35
36 Grattagliano, et al., 2009; Williams, et al., 2010). In the 16 fetuses of our series born to
37
38 eight unrelated families, neuropathological analysis defined a diffuse form of
39
40 encephaloclastic proliferative vasculopathy (EPV), affecting the entire CNS and resulting
41
42 in classical PGV with pterygia and a severe fetal akinesia deformation sequence in 14
43
44 cases. In contrast, two cases from the single family IV presented a more focal form of
45
46 EPV, without spinal cord involvement and subsequent arthrogryposis/pterygia.
47
48 Identification of *FLVCR2* mutations in this family suggests that the anteroposterior extent
49
50 of CNS degeneration can be variable, and that PGV may be an extreme phenotype of a
51
52 broader spectrum of proliferative vasculopathies. Stabilization of newly formed capillary
53
54
55
56
57
58
59
60

1
2
3 sprouts during angiogenesis requires interactions of endothelial cells with mural support
4 cells, known as pericytes. The regionally restricted distribution of PGV in family IV
5 might be linked to the embryonic lineage of the telencephalic pericytes, of a distinct
6 neural crest cell origin from those of the spinal cord (Etchevers, et al., 2001).
7
8 Interestingly, immunostaining for alpha smooth muscle actin (aSMA, a marker for
9 mature pericytes) in fetal PGV brains was drastically reduced in the PGV within the CNS
10 while normal aSMA expression was found in the leptomeninges (Figure 1I). Further
11 studies should elucidate whether this observed effect on pericytes is the primary cause or
12 an effect of this disease.
13
14
15
16
17
18
19
20
21
22
23
24

25
26 Recently, *FLVCR2* mutations were also reported in 5 families with Fowler syndrome
27 (Meyer, et al., 2010), with the same homozygous Thr430Arg mutation in three families,
28 and 2 compound heterozygous cases. Interestingly, Thr430Arg is associated with both
29 forms of the disease, namely with or without spinal cord involvement, suggesting no
30 genotype phenotype correlations. It is noteworthy that the mutation concerned the same
31 codon (Thr430) as in our family IV, the only one of our series without spinal cord
32 involvement. More recently, Lalonde et al. also reported four *FLVCR2* compound
33 mutations in 2 FS families with spinal cord involvement ((Lalonde, et al., 2010).
34 Interestingly, the only missense mutation predicted to be “benign” in our study (L398V)
35 was identified by two distinct approaches in a common case reported by both Lalonde et
36 al. and Meyer et al., adding to the likely pathogenicity of this variation. To sum up, 15
37 different *FLVCR2* mutations (including those described in our study) have now been
38 reported in 13 cases: one large deletion, two nonsense mutations, one splice site mutation,
39 one insertion/deletion change and 10 missense variations.
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 The *FLVCR2* gene encodes a transmembrane protein that belongs to the major facilitator
4
5
6 superfamily (MFS) of secondary carriers that transport small solutes such as calcium
7
8 (Pao, et al., 1991). It is closely related in both sequence and topology to the better-known
9
10 FLVCR1, sharing 60% amino acid identity (Lipovich, et al., 2002). FLVCR1 has been
11
12 identified as the receptor for a feline leukemia virus (FeLV-C), and like FLVCR2 and
13
14 other MFS members, is predicted to contain 12 membrane-spanning segments and six
15
16 extracellular loops. A single mutation in the sixth extracellular loop is sufficient to confer
17
18 FeLV-C receptor activity on FLVCR2, which does not otherwise bind the native
19
20 virus (Brown, et al., 2006). However, FLVCR2 functions as a receptor for the FeLV-C
21
22 variant FY981 (Shalev, et al., 2009). FLVCR1 is found only in hematopoietic tissues, the
23
24 pancreas and kidney (Tailor, et al., 1999), but rodent *Flvcr2* is widely expressed during
25
26 embryonic development, in particular within the CNS and in the vessels of the maturing
27
28 retina, and human FLVCR2, within the fetal pituitary (Brasier, et al., 2004). FLVCR1 has
29
30 been shown to function as a heme exporter, essential for erythropoiesis (Quigley, et al.,
31
32 2004). Interestingly, the five glutamate residues in the C-terminal putative coiled-coiled
33
34 domain of FLVCR2, not present in FLVCR1, may serve an analogous function to the
35
36 same ferric ion-binding glutamate sequence in glycine-extended gastrin, by stimulating
37
38 cell proliferation (He, et al., 2004). Based on the cell types in which it is expressed and
39
40 MFS transport of chelated complexes of divalent metal ions, the FLVCR2 transporter
41
42 was postulated to be a gatekeeper for the controlled entry of calcium into target cell types
43
44 (Brasier, et al., 2004). Calcium signalling is involved in virtually all cellular processes
45
46 and its homeostasis is tightly regulated. Angiogenic factors such as VEGF-A and FGF2
47
48 induce a transient increase of endothelial cell intracellular calcium concentrations , which
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 acts as a second messenger to induce proliferation, among other effects (Tomatis, et al.,
4
5
6 2007). Blood vessels are susceptible to responding to angiogenic signals and undergoing
7
8 calcification when their pericytic coverage has been disrupted (Collett and Canfield,
9
10 2005), both of which signs we have observed in PGV patient brain sections.

11
12
13 **HTS** of the entire exome has been used so far to identify disease-causing genes in the rare
14
15 Miller and Bartter syndromes, respectively (Choi, et al., 2009; Ng, et al., 2010). Recently,
16
17 targeted exon-specific sequencing within a restricted 40 MB linkage interval allowed the
18
19 identification of an additional gene for Familial Exudative
20
21 Vitreoretinopathy (Nikopoulos, et al., 2010). Our study underlines the use of **HTS** for the
22
23 coverage of an entire linkage interval with no compelling candidate genes and no
24
25 justification for the exclusion of non-coding regions. Our nested analysis approach led
26
27 rapidly to the identification of a disease-causing gene. While it further demonstrates the
28
29 power of this new technology, it also highlights other potential risks of missing mutations
30
31 during data analyses. The number of patients, diagnostic accuracy and genetic
32
33 homogeneity allowed us to compensate for low capture efficiency due to suboptimal
34
35 DNA quality, and in the future, as the technology develops, furthering the depth of
36
37 coverage should ensure a better distinction of background from true mutations. Finally,
38
39 identification of the gene for Fowler syndrome will permit accurate genetic counselling
40
41 for PGV and prenatal diagnosis, in particular for the late-onset forms of the disease
42
43 without spinal cord involvement.
44
45
46
47
48
49
50

51
52
53
54
55
56 **COMPETING INTERESTS STATEMENT**
57
58
59
60

1
2
3 The authors declare no competing interests.
4
5
6
7
8
9

10 **ACKNOWLEDGEMENTS**

11
12
13
14 We are grateful to families and to the French Society of Fetal Pathology (SOFFOET) for
15 participating in the study. We thank Chantal Esculpavit for technical help. This work was
16 funded by the GIS-Maladies Rares. ST is supported by grant NS039818 from the US
17 National Institute of Health (NIH).
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Review

REFERENCES

- 1
2
3
4
5
6
7 Benko S, Fantes JA, Amiel J, Kleinjan DJ, Thomas S, Ramsay J, Jamshidi N, Essafi A,
8 Heaney S, Gordon CT and others. 2009. Highly conserved non-coding elements
9 on either side of SOX9 associated with Pierre Robin sequence. *Nat Genet*
10 41(3):359-64.
- 11 Bessieres-Grattagliano B, Foliguet B, Devisme L, Loeuillet L, Marcorelles P, Bonniere
12 M, Laquerriere A, Fallet-Bianco C, Martinovic J, Zrelli S and others. 2009.
13 Refining the clinicopathological pattern of cerebral proliferative glomeruloid
14 vasculopathy (Fowler syndrome): report of 16 fetal cases. *Eur J Med Genet*
15 52(6):386-92.
- 16
17
18 Brasier G, Tikellis C, Xuereb L, Craigie J, Casley D, Kovacs CS, Fudge NJ, Kalnins R,
19 Cooper ME, Wookey PJ. 2004. Novel hexad repeats conserved in a putative
20 transporter with restricted expression in cell types associated with growth,
21 calcium exchange and homeostasis. *Exp Cell Res* 293(1):31-42.
- 22
23
24 Brown JK, Fung C, Tailor CS. 2006. Comprehensive mapping of receptor-functioning
25 domains in feline leukemia virus subgroup C receptor FLVCR1. *J Virol*
26 80(4):1742-51.
- 27
28
29 Choi M, Scholl UI, Ji W, Liu T, Tikhonova IR, Zumbo P, Nayir A, Bakkaloglu A, Ozen
30 S, Sanjad S and others. 2009. Genetic diagnosis by whole exome capture and
31 massively parallel DNA sequencing. *Proc Natl Acad Sci U S A* 106(45):19096-
32 101.
- 33
34
35 Collett GD, Canfield AE. 2005. Angiogenesis and pericytes in the initiation of ectopic
36 calcification. *Circ Res* 96(9):930-8.
- 37
38
39 Corpet F. 1988. Multiple sequence alignment with hierarchical clustering. *Nucleic Acids*
40 *Res* 16(22):10881-90.
- 41
42
43 Etchevers HC, Vincent C, Le Douarin NM, Couly GF. 2001. The cephalic neural crest
44 provides pericytes and smooth muscle cells to all blood vessels of the face and
45 forebrain. *Development* 128(7):1059-68.
- 46
47
48 Fowler M, Dow R, White TA, Greer CH. 1972. Congenital hydrocephalus-hydrencephaly
49 in five siblings, with autopsy studies: a new disease. *Dev Med Child Neurol*
50 14(2):173-88.
- 51
52
53 He H, Shehan BP, Barnham KJ, Norton RS, Shulkes A, Baldwin GS. 2004. Biological
54 activity and ferric ion binding of fragments of glycine-extended gastrin.
55 *Biochemistry* 43(37):11853-61.
- 56
57
58 Kleinjan DA, van Heyningen V. 2005. Long-range control of gene expression: emerging
59 mechanisms and disruption in disease. *Am J Hum Genet* 76(1):8-32.
- 60
61
62 Lalonde E, Albrecht S, Ha KC, Jacob K, Bolduc N, Polychronakos C, Dechelotte P,
63 Majewski J, Jabado N. Unexpected allelic heterogeneity and spectrum of
64 mutations in Fowler syndrome revealed by next-generation exome sequencing.
65 *Hum Mutat*.
- 66
67
68 Lettice LA, Heaney SJ, Purdie LA, Li L, de Beer P, Oostra BA, Goode D, Elgar G, Hill
69 RE, de Graaff E. 2003. A long-range Shh enhancer regulates expression in the
70 developing limb and fin and is associated with preaxial polydactyly. *Hum Mol*
71 *Genet* 12(14):1725-35.

- 1
2
3 Lipovich L, Hughes AL, King MC, Abkowitz JL, Quigley JG. 2002. Genomic structure
4 and evolutionary context of the human feline leukemia virus subgroup C receptor
5 (hFLVCR) gene: evidence for block duplications and de novo gene formation
6 within duplicons of the hFLVCR locus. *Gene* 286(2):203-13.
- 7
8 Meyer E, Ricketts C, Morgan NV, Morris MR, Pasha S, Tee LJ, Rahman F, Bazin A,
9 Bessieres B, Dechelotte P and others. Mutations in FLVCR2 are associated with
10 proliferative vasculopathy and hydranencephaly-hydrocephaly syndrome (Fowler
11 syndrome). *Am J Hum Genet* 86(3):471-8.
- 12
13 Ng SB, Buckingham KJ, Lee C, Bigham AW, Tabor HK, Dent KM, Huff CD, Shannon
14 PT, Jabs EW, Nickerson DA and others. 2010 Exome sequencing identifies the
15 cause of a mendelian disorder. *Nat Genet* 42(1):30-5.
- 16
17 Nikopoulos K, Gilissen C, Hoischen A, van Nouhuys CE, Boonstra FN, Blokland EA,
18 Arts P, Wieskamp N, Strom TM, Ayuso C and others. 2010. Next-generation
19 sequencing of a 40 Mb linkage interval reveals TSPAN12 mutations in patients
20 with familial exudative vitreoretinopathy. *Am J Hum Genet* 86(2):240-7.
- 21
22 Pao GM, Wu LF, Johnson KD, Hofte H, Chrispeels MJ, Sweet G, Sandal NN, Saier MH,
23 Jr. 1991. Evolution of the MIP family of integral membrane transport proteins.
24 *Mol Microbiol* 5(1):33-7.
- 25
26 Quigley JG, Yang Z, Worthington MT, Phillips JD, Sabo KM, Sabath DE, Berg CL,
27 Sassa S, Wood BL, Abkowitz JL. 2004. Identification of a human heme exporter
28 that is essential for erythropoiesis. *Cell* 118(6):757-66.
- 29
30 Shalev Z, Duffy SP, Adema KW, Prasad R, Hussain N, Willett BJ, Tailor CS. 2009.
31 Identification of a feline leukemia virus variant that can use THTR1, FLVCR1,
32 and FLVCR2 for infection. *J Virol* 83(13):6706-16.
- 33
34 Tailor CS, Willett BJ, Kabat D. 1999. A putative cell surface receptor for anemia-
35 inducing feline leukemia virus subgroup C is a member of a transporter
36 superfamily. *J Virol* 73(8):6500-5.
- 37
38 Tomatis C, Fiorio Pla A, Munaron L. 2007. Cytosolic calcium microdomains by
39 arachidonic acid and nitric oxide in endothelial cells. *Cell Calcium* 41(3):261-9.
- 40
41 Wildeman M, van Ophuizen E, den Dunnen JT, Taschner PE. 2008. Improving sequence
42 variant descriptions in mutation databases and literature using the Mutalyzer
43 sequence variation nomenclature checker. *Hum Mutat* 29(1):6-13.
- 44
45 Williams D, Patel C, Fallet-Bianco C, Kalyanasundaram K, Yacoubi M, Dechelotte P,
46 Scott R, Bazin A, Bessieres B, Marton T and others. 2010. Fowler syndrome-a
47 clinical, radiological, and pathological study of 14 cases. *Am J Med Genet A*
48 152A(1):153-60.
49
50
51
52
53
54
55
56
57
58
59
60

LEGENDS TO TABLE AND FIGURES

Figure 1: Marker analysis in Fowler syndrome fetal brain

(A) Cortical plate of Fowler syndrome (FS) fetal brain (family IV) showing abnormal perforating vessels. Note the characteristic thickened vessels (asterisks), ending in glomeruloid formations (arrowheads), often devoid of recognizable lumina. CD34 capillary staining in (B) on a brain from a control, stage matched fetus and (C) from a FS fetus (family I) (C). VEGF immunostaining around (D) a brain parenchymal capillary from a control fetus in which it is essentially absent, and (E) from a FS fetus in which it appears markedly increased. (F) GFAP astroglial immunostaining on a FS fetal brain. Alpha SMA immunostaining of pericytes on (G) a brain section from a control fetus versus (H and I) from two FS fetuses.

Figure 2 : Pedigree and linkage analysis results

Pedigrees of families included in this study. Arrows indicate individuals for whom DNA was available, and arrowheads indicate the samples sequenced by HTS. Homozygosity or linkage was analysed by microsatellite markers analysis and confirmed a founder effect by haplotype identity in 2 Turkish families (I and II) that were later discovered to carry the same *FLVCR2* exon 2 to 10 deletion.

Figure 3 : Summary of HTS data analysis

This diagram illustrates the flowchart of HTS data analysis. After elimination of variants found outside of the mapping region (27% of total variants) and those corresponding to known SNPs (29% of on-target variants) or shared with the control individual E (50% of on-target variants),

1
2
3 HTS identified 54 variants in coding sequences, eight of which were synonymous. The remaining
4
5 46 variants were located in 29 candidate genes, 20 of which were excluded because only one
6
7 variant was identified. Finally, only one gene, *FLVCR2* presented 4 variants.
8
9

10
11 **Figure 4 :** *FLVCR2* deletion and mutations
12
13

14
15 (A) Genome browser view centered on the *FLVCR2* locus (ENSG00000119686) showing all
16
17 variations (red dots) and reads coverage (light blue) in individuals A (fetus, family II) and B
18
19 (fetus, family V). Note the absence of variations and reads in individual A, suggesting a
20
21 homozygous deletion of exons 2 to 10, as well as the 2 final exons of the adjacent *c14orf1*
22
23 transcript (ENSG00000133935). (B) Chromatograms of *FLVCR2* homozygous (upper panel) and
24
25 compound heterozygous mutations (lower panel).
26
27
28
29

30
31 **Figure 5:** Localisation of mutations in *FLVCR2* and conservation of mutated *FLVCR2* amino
32
33 acids.
34
35

36
37 (A) Localization of mutations on a secondary structure prediction of the *FLVCR2* transporter.
38
39 The three homozygous mutations are predicted to alter an amino acid localized in one of the 12
40
41 transmembrane (TM) domains: p.Y134X is located in TM2, p.L359P in TM8, and p.G412R in
42
43 TM10. Compound heterozygous mutations in family VI alter amino acids at the N-terminal
44
45 cytoplasmic end and in the extracellular loop 5 (blue asterisk). Compound heterozygous
46
47 mutations in family IV alter an amino acid predicted to be localized in TM8 and in the
48
49 intracellular loop 5 (green asterisk).
50
51
52

53
54 (B) Alignment and conservation of mutated *FLVCR2* amino acids. Sequences for *FLVCR2* from
55
56 10 different species have been aligned using the Multalin tool ("Multiple sequence alignment
57
58
59
60

1
2
3 with hierarchical clustering" (Corpet, 1988). Highly conserved amino acids are represented in
4
5 red, moderately conserved amino acids are in blue and non-conserved ones are in black. Mutated
6
7 amino acids are boxed.
8
9

10
11 **Table 1** : Analysis of variations by individual and *FLVCR2* variations identified by high-
12 throughput or capillary sequencing.
13
14

15
16
17 E is a healthy brother in family V not carrying the disease allele by haplotyping, and taken as
18
19 healthy control. Mutation numbering is based on cDNA sequence with a 'c.' symbol before the
20
21 number, where +1 corresponds to the A of ATG translation codon (codon 1) of the cDNA
22
23 reference sequences (NM_017791). Mutation names were checked by the Mutalyzer program
24
25 (Wildeman, et al., 2008).
26
27
28
29
30
31
32

33 **Supplementary Table S1**: Analysis of total number of variations detected by high-throughput
34
35 sequencing
36
37
38
39
40

41 **Supplementary Table S2**: Primers and PCR conditions
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60




Figure 1
115x86mm (300 x 300 DPI)

Review

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60




Figure 2
160x160mm (300 x 300 DPI)




Figure 3
154x70mm (300 x 300 DPI)

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60




Figure 4
199x128mm (300 x 300 DPI)




Figure 5
199x149mm (300 x 300 DPI)

Individual	A (Fam II)	B (Fam VI)	C (Fam VII)	D (Fam IV)	F (Fam V)	G (Fam I)	H (Fam III)	Total	
Origin	Turkish	French	French	French	Maroccan	Turkish	French		
Coverage	8,8X	4X	8,6X	2,3X	11,8X	11,6X	6,6X	7X	
Number of Variations (total)	All	2852	1804	2639	823	3067	3841	2005	17 031
	Variations in E removed	1379	790	1154	282	1527	2075	1182	
	SNP removed	565	380	608	112	695	872	821	
	Variations in E and SNPs removed	546	300	465	80	569	750	747	
Number of variations on mRNA	Total	100	74	105	41	87	139	58	
	Variations in E and SNP removed	23	14	17	6	20	26	29	
Number of variations on CDS	Total	41	22	44	13	42	60	25	
	Variations in E and SNP removed	8	2	4	2	11	12	15	
	non synonymous	22	8	23	9	23	28	13	
	non synonymous and SNP removed	8	2	4	2	9	8	9	42
	Next generation sequencing	Del Ex 2-10 hnz	c.402C>G, p.Tyr134S top hnz	c.251G>A, p.Arg84His hnz	c.1056C>G, p.Thr352Arg hnz	c.1234G>C, p.Gly412Arg hnz	(mother)	-	
FLVCR2 variations	Capillary sequencing	Del Ex 2-10 hnz	c.402C>G, p.Tyr134S top hnz	c.251G>A, p.Arg84His hnz c.1192C>G, p.Leu398Val hnz	c.1056C>G, p.Thr352Arg hnz c.1289C>T, p.Thr430Met hnz	c.1234G>C, p.Gly412Arg hnz	Del Ex 2-10 hnz in mother	c.1076T>C, p.Leu359Pro hnz	
	Comparison and reason for discrepancy	confirmation	confirmation	Arg84His: confirmation Leu398Val: 7 reads, 4 with the mutation, but excluded for unidirectionality	T352R: 4 reads of only the mutated allele, T430M: no reads	confirmation	Deletion confirmed in foetuses (hnz), hnz in parents	2 reads of only the mutated allele	

Table 1 : Analysis of variations by individual and *FLVCR2* variations identified by next generation or capillary sequencing. Mutation numbering is based on cDNA sequence with a 'c.' symbol before the number, where +1 corresponds to the A of ATG translation codon (codon 1) of the cDNA reference sequences (NM_017791). Mutation names were checked by the Mutalyzer program (Wildeman, et al., 2008).


Heterozygous and homozygous variations (20-100% of total reads)	All variations	variations on chr 14	% on Chr 14
A + B + C + D + F + G + H	23 262	17 031	73%
A + B + C + D + F + G + H – E (control)	12 942	8 389	65%
A + B + C + D + F + G + H – E –HapMap	10 177	5 763	57%
A + B + C + D + F + G + H – E –dbSNP	6 553	3 457	52%
A + B + C + D + F + G + H – E –hapMap – dbSNP	6 552	3 457	52%
A + B + C + D + F + G + H – E –hapMap – dbSNP : mRNA (UTR et CDS)	179	135	75%
A + B + C + D + F + G + H – E –hapMap – dbSNP : CDS	63	54	85%
A + B + C + D + F + G + H – E –hapMap – dbSNP : CDS, non synonymous	49	42	85%

Supplementary Table 1
Analysis of Total Number of variations

Primers	Sequence	PCR size
FLVCR2-1AF	GCCTCTAGTCTCTGTTTCTTCTGG	527
FLVCR2-1AR	TCAGCATGTAGCACATGGAC	
FLVCR2-1BF	TGTGCAACTCCTTTCAGTGG	527
FLVCR2-1BR	CAATCACTGCCTGTACACC	
FLVCR2-2F	TCTCTGGTGTGTTTGGAGGTGAGA	397
FLVCR2-2R	CATGGTATTTTCAGGGCATGTT	
FLVCR2-3F	TTCACTCAGCCTCAAACAATG	
FLVCR2-3R	TAGCTGGGTCCTCTGGATTG	
FLVCR2-4F	TGTGTGGCTAAGGGAAGGTT	464
FLVCR2-4R	GGTTGAGATCTAGGGCCATCT	
FLVCR2-5F	TCTCCTAGGCCATCTTGTC	363
FLVCR2-5R	CTTGCCACTAGGATCTCCA	
FLVCR2-6F	GGCAACAGAGCAAGACACTG	382
FLVCR2-6R	TCAGTTAGAAGGCAGCAAAGG	
FLVCR2-7F	CCCAGATCATTAGAGGGCCTA	596
FLVCR2-8R	CCAACAAACCCTTCCATCTG	
FLVCR2-9F	CCTGTGACCCTTAGGAAATGA	292
FLVCR2-9R	TGCCATGTGTAAGGGATGAA	
FLVCR2-10F	TTTCTTGGCTCTCTGGGATG	486
FLVCR2-10R	TATTCTCTGCCACCCTGTCC	
Primers used for cloning the deletion breakpoints of families I and II		
FLVCR1-i1	CAGGATAAGCTCCATCATCCTTAC	
C14orf1-3Fex	CTCGGACCTTTGGGATCTG	

Supplementary Table 2
Primers and PCR conditions



1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60



115x86mm (300 x 300 DPI)

Review

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60



199x128mm (300 x 300 DPI)

Review




Figure 5
199x149mm (300 x 300 DPI)